$5.09
+0.06 (+1.19%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CSBR is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 2 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC) · FINRA short interest 9.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent SarcomaNCT02720796Number of patients' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment.Open-label · Diagnostic | Not applicable | Terminatedsponsor's stated reason: Recruitment barriers | Other: PDX drug sensitivity testing | Sarcoma | 17 | 2017-11-30 | 2017-10-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19